A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia

Neurodegenerative Diseases

Volumn 4, Issue 2-3, 2007, Pages 185-194

  Petzold, A ^a   Keir, G ^a   Warren, J ^a   Fox, N ^a   Rossor, M N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cerebrospinal fluid; Dementia; Neurofilaments

Indexed keywords

BIOLOGICAL MARKER; NEUROFILAMENT PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANALYTIC METHOD; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; FRONTOTEMPORAL DEMENTIA; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; META ANALYSIS; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL; QUALITY CONTROL; SCREENING TEST; SYSTEMATIC REVIEW;

BIOLOGICAL MARKERS; DEMENTIA; NEUROFILAMENT PROTEINS;

EID: 34347255707     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000101843     Document Type: Article

References (35)

1. Cummings JL: Alzheimer's disease. N Engl J Med 2004;351:56-67.
2. Wiltfang J, Lewczuk P, Riederer P, Grunblatt E, Hock C, Scheltens P, Hampel H, Vanderstichele H, Iqbal K, Galasko D, Lannfelt L, Otto M, Esselmann H, Henkel AW, Kornhuber J, Blennow K: Consensus paper of the WFSBP Task Force on Biological Markers of Dementia: the role of CSF and blood analysis in the early and differential diagnosis of dementia. World J Biol Psychiatry 2005;6:69-84.
3. Petzold A: Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 2005;233:183-198.
4. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
5. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF: Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-1554.
6. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
7. Sjogren M, Rosengren L, Minthon L, Davidsson P, Blennow K, Wallin A: Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology 2000;54:1960-1904.
8. Sjogren M, Blomberg M, Jonsson M, Wahlund LO, Edman A, Lind K, Rosengren L, Blennow K, Wallin A: Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res 2001;66:510-506.
9. Folstein M, Folstein S, McHugh P: 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychol Res 1975;12:189-198.
10. Morris JC: The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2404.
11. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C: Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-2018.
12. Rosengren LE, Karlsson JE, et al: Neurofilaments protein levels in CSF are increased in dementia. Neurology 1999;52:1090-1093.
13. Andreasen N, Gottfries J, Vanmechelen E, Vanderstichele H, Davidson P, Blennow K, Rosengren L, Blennow K: Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;71:557-508.
14. Wallin A, Sjogren M: Cerebrospinal fluid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech Age Dev 2001;122:1937-1949.
15. Sjogren M, Wallin A: Pathophysiological aspects of frontotemporal dementia - emphasis on cytoskeleton proteins and autoimmunity. Mech Age Dev 2001;122:1923-1935.
16. Hu YY, He SS, Wang XC, Duan QH, Khatoon S, Iqbal K, Grundke-Iqbal I, Wang JZ: Elevated levels of phosphorylated neurofilament proteins in cerebrospinal fluid of Alzheimer disease patients. Neurosci Lett 2002;320:156-160.
17. Norgren N, Rosengren L, Stigbrand T: Elevated neurofilament levels in neurological diseases. Brain Res 2003;987:25-31.
18. Brettschneider J, Petzold A, Claus A, Riepe M, Tumani H: The Neurofilament heavy chain (NfH-SMI35) in the cerebrospinal fluid diagnosis of Alzheimer disease. Dement Geriatr Cogn Disord 2006;21:291-295.
19. Pijnenburg YAL, Janssen JC, Schoonenboom NSM, Petzold A, Mulder C, Stigbrand T, Norgren N, Heijst H, Hac CE, Scheltens P, Teunissen CE: CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. Dement Geriatr Cogn Disord. In press.
20. Petzold A, Keir G, Warren J, Fox NC, Rossor M: The value of lumbar cerebrospinal fluid levels of neurofilaments in the differential diagnosis of patients with dementia. 16th Meeting of the European Neurological Society, Lausanne, 2006. J Neurol 2006;253:SII39-SII40.
21. Hu YY, He SS, Wang X, Duan QH, Grundke-Iqbal I, Iqbal K, Wang J: Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am J Pathol 2002;160:1269-1278.
22. Petzold A, Keir G, Green AJE, Giovannoni G, Thompson EJ: A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-190.
23. Josephs KA, Knopman DS, Whitwell BA, Boeve BF, Parisi JE, Petersen RC, Dickson DW: Survival in two variants of tau-negative frontotemporal lobar degeneration: FTLDU vs. FTLD-MND. Neurology 2005;65:645-647.
24. Brettschneider J, Petzold A, Suessmuth SD, Ludolph AC, Tumani H: Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-856.
25. Josephs KA, Holton JL, Rossor MN, Braendgaard H, Ozawa T, Fox NC, Petersen RC, Pearl GS, Ganguly M, Rosa P, Laursen H, Parisi JE, Waldemar G, Quinn NP, Dickson DW, Revesz T: Neurofilament inclusion body disease: a new proteinopathy? Brain 2003;126:2291-2503.
26. Uchikada H, Shaw G, Wang DS, Dickson DW: Screening for neurofilament inclusion body disease using α-internexin immunohistochemistry. Neurology 2005;64:1658-1659.
27. Holmberg B, Rosengren L, Karlsson JE, Johnels B: Increased cerebrospinal fluid levels of neurofilament protein in progressive supra-nuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov Disord 1998;13:70-77.
28. Brettschneider J, Petzold A, Sussmuth SD, Landwehrmeyer GB, Ludolph AC, Kassubek J, Tumani H: Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes. Mov Disord 2006;21:2224-2227.
29. Abdo WF, van de Warrenburg BP, Munneke M, van Geel WJ, Bloem BR, Kremer HP, Verbeek MM: CSF analysis differentiates multiple-system atrophy from idiopathic lateonset cerebellar ataxia. Neurology 2006;67:474-479.
30. Holmberg B, Johnels B, Ingvarsson P, Eriksson B, Rosengren L: CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes. Parkinsonism Relat Disord 2001;8:23-31.
31. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M: Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006;5:343-354.
32. Shaw G, Yang C, Ellis R, Anderson K, et al: Hyperphosphorylated neurofilament NF-H is a serum biomarker for axonal injury. Biochem Biophys Res Comm 2005;336:1268-1277.
33. Petzold A, Shaw G: Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods 2007;319:34-40.
34. Van Geel WJA, Rosengren LE, and Verbeek MM: An enzyme immunoassay to quantify neurofilament light chain in cerebrospinal fluid. J Immunol Methods 2005;296:179-185.
35. Norgren N, Karlsson JE, Rosengren L, Stigbrand T: Monoclonal antibodies selective for low molecular weight neurofilaments. Hybrid Hybridomics 2002;21:53-59.